|
Indications and Dosage
Oral
Treatment and prophylaxis of relapse of Plasmodium vivax malaria Adult: 25 mg once daily for 7 days. To be used in comjunction with chloroquine.
|
|
Contraindications
Rheumatoid arthritis; systemic lupus erythematosus. Co-administration of drugs known to cause haemolysis.
|
|
Special Precautions
Exercise caution while administering bulaquine to patients suffering from G6PD deficiency. Pregnancy and lactation, children.
|
|
Drug Interactions
Specific studies with other drugs have not been undertaken except with chloroquine where it was concurrently used in the phase II/III clinical trials without any adverse effects.
|
|
Action
Description:
Mechanism of Action: Bulaquine is a new generation of 8-aminoqinoline derivative antimalarial used in managing P. vivax infection. It reportedly inhibits protein synthesis in protozoa and polymerization of amino acids by the plasmodia. When co-administered with chloroquine, malarial is treated witho significant relapse episodes. Compared to primaquine, it requires lesser treatment days and it has better tolerance profile in patients with G6PD (G6PDH) deficiency. |
|
MIMS Class
|
Sign Out
